PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $21.5M Series E financing. Participants have included Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland Oakwood Medical Investors.

Note: 2009 [...]

Accumetircs (San Diego,CA) a commercial-stage diagnostic company focused on VerifyNow® System, a comprehensive suite of tests for the assessment of platelet response to antiplatelet therapies, closed a $16.5M Series E financing. Participants inlcude Arnerich Massena, BBT Fund/Apothecary Capital, Essex Woodlands Health Ventures, Kaiser Permanente Ventures and RiverVest Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming [...]

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $21.5 Series E financing. Participants have included Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capital and Oakwood Medical Investors.
Note: [...]

Calypso Medical Technologies (Seattle, WA) a commercial-stage medical device company focused on implantable sensor electromagnetic transponders, to accurately and continuously pinpoint the location of tumors in real-time during radiation therapy delivery, closed a $50M Series E financing. Participants include Skyline Ventures, Frazier Healthcare Ventures, Bay City Capital and InterWest Partners.

Agendia (The Netherlands) a commercial-stage molecular diagnostics company focused on gene expression profiling and patient stratification in breast and colon cancers, closed a $25M Series E financing. Participants have included ING, Van Herk Biotech, Gilde Healthcare Partners and Global Life Science Ventures.

Pacific Biosciences (Menlo Park, CA) developer of single molecule real-time DNA sequencing system, closed a $68M Series E financing. Participants include Monsanto, Wellcome Trust, Sutter Hill Ventures, Deerfield Management, Intel Capital, Morgan Stanley, Redmile Group, T. Rowe Price, Mohr Davidow Ventures, Kleiner Perkins, Alloy Ventures, Maverick Capital, AllianceBernstein, DAG Ventures, Teachers’ Private Capital and Blackstone [...]

Chimerix (Durham, NC) a clinical-stage developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $16M Series E financing. Participants include Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company.

Paradigm Spine (New York, NY) a clinical-stage medical device company focused on lumbar stabilization and interspinous implants, closed a $6.5M Series E financing. Participants include Praefinium Group and Trevi Health Ventures.

Medivance (Louisville, KY) a commercial-stage device company focused on non-invasive core temperature management, closed a $8.1M Series E financing. Participants include Quellos Private Capital, MDY Healthcare, Cross Atlantic Partners, Skyline Ventures, Camden Partners, Partisan Management Group, Nikko Synergy Ventures, Kimberly-Clark, CSFB Private Equity and New England Capital Partners.

Atritech (Plymouth, MN) a clinical-stage medical device company focused on developing minimally invasive technologies designed for the prevention of atrial fibrillation related stroke, closed a $30M Series E financing. Participants include Thomas, McNerney & Partners, Split Rock Partners, Prism VentureWorks, Tullis-Dickerson and Vector Group.

Surface Logix (Brighton, MA) a clinical-stage small molecule company focused on metabolic and cardiovascular disease, closed a $15M Series E financing. Participants include ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Co., Unilever Technology Ventures and Venrock.

Symphogen (Denmark) a clinical-stage developer of recombinant polyclonal antibodies for the treatment of thrombocytopenia and hemolytic disease, closed a $42.3M Series E financing. Participants include Essex Woodlands Health Ventures, Novo, Takeda Research Investment and Gilde Healthcare Partners.